GGrantIndex
← Leaderboards

James J Kobie

University Of Alabama At Birmingham

Google Scholar ↗PubMed ↗ORCID ↗
$11,682,706
Attributed
$15,984,863
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY2015–25
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,984,863 · 7

By mechanism

R01$15,562,738 · 6
R21$422,125 · 1

Top collaborators

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “Infection”

Research focus

InfectionVaccinesResponseB-LymphocytesMediatingVirusAntibodiesFutureAntibody ResponseProteinsResolutionImmunizationInsightVaccinationPhenotypeAntigensImmunoglobulin GHiv VaccineImmunoglobulinsVaccine DevelopmentNeutralizing AntibodyCellsPeripheral BloodTransmission Process

Grant awards (22)

Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use$1,107,091
R01 · FY2025 · DA · contact PI
Origins and dynamics of HIV gp120 specific B cell memory in HIV negative high-risk individuals$742,053
R01 · FY2025 · AI · contact PI
Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use$1,086,368
R01 · FY2024 · DA · contact PI
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies$841,341
R01 · FY2024 · AI · contact PI
Origins and dynamics of HIV gp120 specific B cell memory in HIV negative high-risk individuals$667,848
R01 · FY2024 · AI · contact PI
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies$841,228
R01 · FY2022 · AI · contact PI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$759,187
R01 · FY2022 · AI · contact PI
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies$856,430
R01 · FY2021 · AI · contact PI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$758,319
R01 · FY2021 · AI · contact PI
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIV$633,200
R01 · FY2021 · DE · contact PI
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIV$777,281
R01 · FY2020 · DE · contact PI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$757,938
R01 · FY2020 · AI · contact PI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$750,079
R01 · FY2019 · AI · contact PI
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIV$732,179
R01 · FY2019 · DE · contact PI
Targeting IgM Memory to Establish Protective B Cell Responses to HIV$830,527
R01 · FY2018 · AI · contact PI
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIV$754,311
R01 · FY2018 · DE · contact PI
Targeting IgM Memory to Establish Protective B Cell Responses to HIV$807,376
R01 · FY2017 · AI · contact PI
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIV$775,239
R01 · FY2017 · DE · contact PI
Targeting IgM Memory to Establish Protective B Cell Responses to HIV$533,505
R01 · FY2016 · AI · contact PI
The Origin and Fate of Human HIV-Specific Plasma Cells Following Vaccination$115,125
R21 · FY2016 · AI · contact PI
Targeting IgM Memory to Establish Protective B Cell Responses to HIV$551,238
R01 · FY2015 · AI · contact PI
The Origin and Fate of Human HIV-Specific Plasma Cells Following Vaccination$307,000
R21 · FY2015 · AI · contact PI